Mizuho lowers BridgeBio Pharma price target to $96
Mizuho analyst Salim Syed maintained an Outperform rating on BridgeBio Pharma (NASDAQ: BBIO) but lowered the price target to $96 from $106, signaling a revised valuation outlook while retaining a positive performance expectation.
*this image is generated using AI for illustrative purposes only.
Mizuho analyst Salim Syed has maintained an Outperform rating on BridgeBio Pharma (NASDAQ: BBIO) while adjusting the valuation outlook. The firm lowered the price target to $96, down from the previous $106.
The revision reflects a reassessment of the company's stock price potential despite the continued positive performance expectation. The Outperform rating indicates that the stock is still expected to perform better than the broader market average.
Rating and Price Target Details
The following table outlines the updated analyst metrics for BridgeBio Pharma:
| Metric | Value |
|---|---|
| Rating | Outperform |
| Previous Price Target | $106 |
| New Price Target | $96 |
The adjustment in the price target suggests a recalibration of the stock's near-term valuation targets without altering the fundamental bullish stance on the company's prospects.
What specific factors led Mizuho to lower the price target despite maintaining an Outperform rating?
How might this price target adjustment influence investor sentiment toward BridgeBio Pharma in the near term?
What upcoming catalysts or milestones could drive BridgeBio's stock performance closer to the new $96 target?
18
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
